Specific immune cells called macrophages in cystic fibrosis (CF) are unable to kill the bacteria Burkholderia cenocepacia due to…
Articles by Patricia Inácio, PhD
The Cystic Fibrosis Foundation (CFF) awarded up to $3.75 million to Matinas BioPharma to support preclinical studies of…
New findings from animal studies support the safety and effectiveness of KB407, a potential inhaled gene therapy for cystic fibrosis, its…
Patient enrollment and dosing has resumed in a Phase 1/2 clinical trial testing MRT5005, Translate Bio‘s potential messenger RNA…
The Cystic Fibrosis Foundation (CFF) has awarded funding to enGene to support its work on a non-viral and inhalable gene…
A Phase 2 clinical trial investigating MS1819 in combination with stable pancreatic enzyme replacement therapy (PERT) to treat exocrine pancreatic insufficiency (EPI) in…
Factors such as diabetes, a specific type of fungal infection, and previous mild to moderate episodes of hemoptysis, or coughing…
ContraFect will receive funding from the Cystic Fibrosis Foundation to conduct preclinical research about the potential of direct…
New research unveils why the bacteria Pseudomonas aeruginosa cause sustained infections in younger cystic fibrosis (CF) patients, while the…
A new study will assess the real-world effects of Vertex Pharmaceutical‘s Trikafta, a triple combo of elexacaftor,…